-
公开(公告)号：EP1385529A4
公开(公告)日：2007-05-09
申请号：EP02714885
申请日：2002-02-06
发明人： LEE FRANCIS Y F
IPC分类号： A61K31/70 , A61K45/00 , A61K31/395 , A61K31/425 , A61K31/427 , A61P35/00
CPC分类号： A61K31/395 , A61K31/427 , Y10S514/922 , A61K2300/00
-
公开(公告)号：EP1181013B1
公开(公告)日：2006-10-11
申请号：EP00922237.3
申请日：2000-04-14
发明人： PARDEE, Arthur, B. , LI, Chiang, J. , LI, You-Zhi
IPC分类号： A61K31/352 , A61K31/337 , A61P35/00
CPC分类号： A61K31/337 , A61K31/122 , A61K31/35 , A61K45/06 , Y10S514/922 , A61K31/335 , A61K2300/00
摘要： We have discovered that the administration of a G1 and/or S phase drug such as beta-lapachone in combination with a G2/M drug such as a taxane derivative such as paclitaxel resulted in a unexpected greater than additive (i.e., synergistic) reduction in the number of tumors (and tumor volume) as compared with the administration of these agents alone. In addition, no signs of toxicity or weight loss were observed. The present invention relates to a method for treating a mammalian tumor using combinations such as a taxane derivative, preferably paclitaxel, and a beta-lapachone, or a derivative or analog thereof.
-
3.发明公开A pyrrolidineacetamide derivative alone in combination for treatment of CNS disorders 审中-公开联合使用单独的吡咯烷乙酰胺衍生物用于治疗CNS病症
公开(公告)号：EP1600167A2
公开(公告)日：2005-11-30
申请号：EP05019209.5
申请日：2000-11-27
申请人： UCB, S.A.
IPC分类号： A61K45/06 , A61P25/28 , A61K31/4015 , A61K31/19
CPC分类号： A61K45/06 , A61K31/19 , A61K31/40 , A61K31/4015 , A61K31/515 , A61K31/55 , A61K31/56 , Y10S514/922 , A61K2300/00
摘要： A use of (S)-(-)-α-ethyl-2-oxo-1-pyrrolidineacetamide for the manufacture of a medicament for treatment of particular diseases and new pharmaceutical compositions comprising (S)-(-)-α-ethyl-2-oxo-1-pyrrolidineacetamide.
摘要翻译： （S） - （ - ） - α-乙基-2-氧代-1-吡咯烷乙酰胺在制备用于治疗特定疾病的药物中的用途以及包含（S） - （ - ） - α-乙基 - 2-氧代-1-吡咯烷乙酰胺。
-
公开(公告)号：EP0933995B1
公开(公告)日：2004-11-17
申请号：EP97940974.5
申请日：1997-09-10
CPC分类号： A61K38/1816 , Y10S514/922
摘要： The use of human erythropoietin (EPO) to prevent or treat endothelial injury due to chemotherapy, radiation therapy, mechanical trauma, or to a disease state which damages the endothelium (such as inflammation, heart disease or cancer) is described. The use of EPO in conjuction with the administration of chemotherapeutic agents is described.
-
公开(公告)号：EP1369122A4
公开(公告)日：2004-05-06
申请号：EP02708862
申请日：2002-02-20
发明人： SHIPOV VALERY PAVLOVICH , TROFIMOV VALERY AFANASIEVICH D , PIGAREV EVGENY SERGEEVICH , POPOV ALEKSANDR IVANOVICH , IVANOV VIKTOR NIKOLAEVICH
CPC分类号： A61K33/14 , A61K33/24 , A61K35/10 , Y10S514/922 , A61K2300/00
摘要： An anticancer agent containing platinum preparation, humic substances, water and sodium chloride. Potassium tetrachloroplatinate is used as a platinum compound and lignohumic acid ammonium salts are used as humic substances taken in the following ratio of components per 1 ml of solution:
-
6.发明公开Combined angiotensin II antagonists and carbonic anhydrase inhibitors for treatment of glaucoma 审中-公开合并Angotensin-II抑制剂和碳酸酐酶抑制剂用于治疗青光眼的治疗
公开(公告)号：EP1344534A3
公开(公告)日：2004-01-02
申请号：EP03013532.1
申请日：2000-12-01
发明人： Yokoyama, Tomihisa
IPC分类号： A61K45/06 , A61K31/4178 , A61K31/41 , A61K31/437 , A61K31/4439 , A61P43/00 , A61P27/06 , A61K31/535 , A61K31/557 , A61K31/415
CPC分类号： A61K45/06 , A61K31/41 , A61K31/415 , A61K31/44 , A61K31/535 , A61K31/55 , A61K31/557 , Y10S514/913 , Y10S514/922 , A61K31/38 , A61K2300/00
摘要： An agent for the prophylaxis or treatment of glaucoma, which comprises an angiotensin II antagonist and at least one compound selected from adrenaline receptor blockers, prostaglandins and carbonic anhydrase inhibitors as active ingredients for simultaneous, separate or successive use of these active ingredients.
-
公开(公告)号：EP1369122A1
公开(公告)日：2003-12-10
申请号：EP02708862.4
申请日：2002-02-20
发明人： SHIPOV, Valery Pavlovich , TROFIMOV, Valery Afanasievich DI , PIGAREV, Evgeny Sergeevich , POPOV, Aleksandr Ivanovich , IVANOV, Viktor Nikolaevich
CPC分类号： A61K33/14 , A61K33/24 , A61K35/10 , Y10S514/922 , A61K2300/00
摘要： An anticancer agent containing platinum preparation, humic substances, water and sodium chloride.
Potassium tetrachloroplatinate is used as a platinum compound and lignohumic acid ammonium salts are used as humic substances taken in the following ratio of components per 1 ml of solution:
lignohumic acid ammonium salts
0.18-0.22 mg
potassium tetrachloroplatinate
0.020-0.040 mg
sodium chloride isotonic solution
0.97-0.99 ml
distilled water
up to 1.0 ml摘要翻译： 含有铂制剂，腐殖质，水和氯化钠的抗癌剂。 使用四氯铂酸钾作为铂化合物，并且使用木质素酸铵盐作为以每1ml溶液的以下组分比例摄取的腐殖质：
-
公开(公告)号：EP1067934B1
公开(公告)日：2003-11-26
申请号：EP99917956.7
申请日：1999-03-29
申请人： Akzo Nobel N.V.
IPC分类号： A61K31/495 , A61K9/08
CPC分类号： A61K9/0095 , A61K31/55 , Y10S514/922 , Y10S514/97 , Y10S514/973 , Y10S514/974
摘要： For the oral administration of the anti-depressant mirtazapine an aqueous solution or suspension is found which is preferably stabilised by methionine, is thickened, and which has a pH of from 2.5 to 3. By the formulation according to the invention, an undesirable local anaesthetic effect of mirtazapine is avoided.
-
公开(公告)号：EP1281400A3
公开(公告)日：2003-11-05
申请号：EP02023033.0
申请日：1996-07-12
申请人： Novartis AG , Novartis Pharma GmbH
IPC分类号： A61K31/445 , A61K9/14 , A61K47/48
CPC分类号： A61K31/4745 , A61K9/145 , A61K9/146 , A61K31/436 , A61K31/445 , Y10S514/885 , Y10S514/922 , Y10S514/95 , Y10S514/964 , Y10S514/97
摘要： A pharmaceutical composition for oral administration in the form of a solid dispersion comprising an ascomycin or a derivative thereof and a carrier medium.
摘要翻译： 以固体分散体形式用于口服给药的药物组合物，其包含子囊霉素或其衍生物和载体介质。
-
10.发明公开Combined angiotensin II antagonists and adrenaline receptor blockers for treatment of glaucoma 审中-公开Kombinierte血管紧张素Ⅱ型血液和肾上腺素Rezeptor Hemmer zur Behandlung von Glaukom
公开(公告)号：EP1344535A2
公开(公告)日：2003-09-17
申请号：EP03013533.9
申请日：2000-12-01
发明人： Yokoyama, Tomihisa
CPC分类号： A61K45/06 , A61K31/41 , A61K31/415 , A61K31/44 , A61K31/535 , A61K31/55 , A61K31/557 , Y10S514/913 , Y10S514/922 , A61K31/38 , A61K2300/00
摘要： An agent for the prophylaxis or treatment of glaucoma, which comprises an angiotensin II antagonist and at least one compound selected from adrenaline receptor blockers, prostaglandins and carbonic anhydrase inhibitors as active ingredients for simultaneous, separate or successive use of these active ingredients.
摘要翻译： 用于预防或治疗青光眼的药剂，其包含血管紧张素II拮抗剂和至少一种选自肾上腺素受体阻断剂，前列腺素和碳酸酐酶抑制剂的化合物作为用于同时，分别或连续使用这些活性成分的活性成分。
-
-
-
-
-
-
-
-
-
搜索结果
249 条记录 (耗时 0.013 秒)
